Analysts' ratings for Halozyme Therapeutics (NASDAQ:HALO) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 3 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 3 | 1 | 1 | 0 | 0 |
Analysts have recently evaluated Halozyme Therapeutics and provided 12-month price targets. The average target is $53.78, accompanied by a high estimate of $72.00 and a low estimate of $40.00. Observing a 4.77% increase, the current average has risen from the previous average price target of $51.33.
Investigating Analyst Ratings: An Elaborate Study
The standing of Halozyme Therapeutics among financial...
Login or create a forever free account to read this news
Sign up/Log in